Alnylam Pharma(CH:DUL)
CHF 138.580.00 (0.00%)
CH:DUL
Alnylam Pharma earnings date
CHF 138.58
At close:0.00 (0.00%)
Alnylam Pharma (DUL) Q1 2026 Earnings Report
0 Followers
CH:DUL Q1 2026 EPS Results
- Actual EPS
- CHF 1.25
- Consensus EPS
- CHF 0.72
- Beat/Miss
- Beat by +CHF 0.53
- One Year Ago EPS
- -CHF 0.36
CH:DUL Q1 2026 Revenue Results
- Actual Revenue
- CHF 963.42M
- Expected Revenue
- CHF 920.77M
- Beat/Miss
- Beat by +CHF 42.64M
- YoY Revenue Growth
- +96.43%
Earnings Announcement Details
- Quarter
- Q1 2026
- Date
- 04/30/2026
- Time
- Before Open
- Conference Call
- Thursday, April 30, 2026
CH:DUL Upcoming Earnings
Alnylam Pharma's next earnings date is estimated for February 18, 2027, based on past reporting schedules.
Q1 2026 Earnings Call Audio
CH:DUL Q1 2026 Earnings Call
0:00 / 0:00
Q1 2026 Earnings Slide Deck
Q1 2026 Earnings Call Summary
No earnings call summary is available for this earnings event.
CH:DUL Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 18, 2027 | 2026 (Q4) | 1.42- | 0.68 | ― | ― |
| Oct 29, 2026 | 2026 (Q3) | 1.3712.98 | 1.52 | 754.35% (+11.46) | |
| Jul 30, 2026 | 2026 (Q2) | 1.351.00 | -0.42 | 337.25% (+1.42) | |
| Apr 30, 2026 | 2026 (Q1) | 0.721.25 | -0.36 | 443.18% (+1.61) | |
| Feb 12, 2026 | 2025 (Q4) | 0.950.68 | -0.54 | 226.15% (+1.21) | |
| Oct 30, 2025 | 2025 (Q3) | 0.461.52 | -0.72 | 311.49% (+2.24) | |
| Jul 31, 2025 | 2025 (Q2) | -0.45-0.42 | -0.11 | -292.31% (-0.31) | |
| May 01, 2025 | 2025 (Q1) | -0.73-0.36 | -0.43 | 15.38% (+0.07) | |
| Feb 13, 2025 | 2024 (Q4) | -0.49-0.54 | -0.91 | 40.91% (+0.37) | |
| Oct 31, 2024 | 2024 (Q3) | -0.76-0.72 | 0.95 | -175.65% (-1.67) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
